Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France. more
Time Frame | NBTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -3.01% | 1.76% | -2.5% |
1-Month Return | -12.91% | 0.33% | -3.91% |
3-Month Return | -40.94% | -8.58% | -0.59% |
6-Month Return | -46.98% | -4.26% | 3.45% |
1-Year Return | -63.01% | 1.27% | 22.31% |
3-Year Return | -68.38% | 5.33% | 25% |
5-Year Return | -82.92% | 38.09% | 77.23% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 68.00K | 50.00K | 10.00K | 4.78M | 30.06M | [{"date":"2019-12-31","value":0.23,"profit":true},{"date":"2020-12-31","value":0.17,"profit":true},{"date":"2021-12-31","value":0.03,"profit":true},{"date":"2022-12-31","value":15.89,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | - | - | - | 985.00K | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | 68.00K | 50.00K | 10.00K | 3.79M | 30.06M | [{"date":"2019-12-31","value":0.23,"profit":true},{"date":"2020-12-31","value":0.17,"profit":true},{"date":"2021-12-31","value":0.03,"profit":true},{"date":"2022-12-31","value":12.61,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 100.00% | 79.38% | 100.00% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":79.38,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 46.85M | 36.53M | 47.17M | 46.70M | 56.84M | [{"date":"2019-12-31","value":82.42,"profit":true},{"date":"2020-12-31","value":64.27,"profit":true},{"date":"2021-12-31","value":83,"profit":true},{"date":"2022-12-31","value":82.17,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (46.78M) | (36.43M) | (52.58M) | (46.70M) | (26.78M) | [{"date":"2019-12-31","value":-4677900000,"profit":false},{"date":"2020-12-31","value":-3642800000,"profit":false},{"date":"2021-12-31","value":-5257900000,"profit":false},{"date":"2022-12-31","value":-4670200000,"profit":false},{"date":"2023-12-31","value":-2677900000,"profit":false}] |
Total Non-Operating Income/Expense | (8.69M) | 7.29M | 11.16M | (22.77M) | (19.28M) | [{"date":"2019-12-31","value":-77.84,"profit":false},{"date":"2020-12-31","value":65.29,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-203.97,"profit":false},{"date":"2023-12-31","value":-172.75,"profit":false}] |
Pre-Tax Income | (50.91M) | (33.61M) | (47.00M) | (57.03M) | (39.58M) | [{"date":"2019-12-31","value":-5091200000,"profit":false},{"date":"2020-12-31","value":-3361400000,"profit":false},{"date":"2021-12-31","value":-4699900000,"profit":false},{"date":"2022-12-31","value":-5703300000,"profit":false},{"date":"2023-12-31","value":-3958000000,"profit":false}] |
Income Taxes | 3.00K | 9.00K | 5.00K | 10.00K | 120.00K | [{"date":"2019-12-31","value":2.5,"profit":true},{"date":"2020-12-31","value":7.5,"profit":true},{"date":"2021-12-31","value":4.17,"profit":true},{"date":"2022-12-31","value":8.33,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (50.91M) | (33.62M) | (47.00M) | (57.04M) | (39.70M) | [{"date":"2019-12-31","value":-5091500000,"profit":false},{"date":"2020-12-31","value":-3362300000,"profit":false},{"date":"2021-12-31","value":-4700400000,"profit":false},{"date":"2022-12-31","value":-5704300000,"profit":false},{"date":"2023-12-31","value":-3970000000,"profit":false}] |
Income From Continuous Operations | (50.91M) | (33.62M) | (47.00M) | (57.04M) | (39.70M) | [{"date":"2019-12-31","value":-5091500000,"profit":false},{"date":"2020-12-31","value":-3362300000,"profit":false},{"date":"2021-12-31","value":-4700400000,"profit":false},{"date":"2022-12-31","value":-5704300000,"profit":false},{"date":"2023-12-31","value":-3970000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (50.91M) | (33.62M) | (47.00M) | (57.04M) | (39.70M) | [{"date":"2019-12-31","value":-5091500000,"profit":false},{"date":"2020-12-31","value":-3362300000,"profit":false},{"date":"2021-12-31","value":-4700400000,"profit":false},{"date":"2022-12-31","value":-5704300000,"profit":false},{"date":"2023-12-31","value":-3970000000,"profit":false}] |
EPS (Diluted) | - | (0.52) | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-51.58,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
NBTX | |
---|---|
Cash Ratio | 1.17 |
Current Ratio | 1.42 |
Quick Ratio | 1.38 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NBTX | |
---|---|
ROA (LTM) | -22.02% |
ROE (LTM) | -198.69% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NBTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.25 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.25 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NBTX | |
---|---|
Trailing PE | NM |
Forward PE | 48.31 |
P/S (TTM) | 3.42 |
P/B | 65.02 |
Price/FCF | NM |
EV/R | 3.41 |
EV/Ebitda | NM |
Nanobiotix (NBTX) share price today is $2.9
Yes, Indians can buy shares of Nanobiotix (NBTX) on Vested. To buy Nanobiotix from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NBTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Nanobiotix (NBTX) via the Vested app. You can start investing in Nanobiotix (NBTX) with a minimum investment of $1.
You can invest in shares of Nanobiotix (NBTX) via Vested in three simple steps:
The 52-week high price of Nanobiotix (NBTX) is $8.96. The 52-week low price of Nanobiotix (NBTX) is $2.76.
The price-to-earnings (P/E) ratio of Nanobiotix (NBTX) is
The price-to-book (P/B) ratio of Nanobiotix (NBTX) is 65.02
The dividend yield of Nanobiotix (NBTX) is 0.00%
The market capitalization of Nanobiotix (NBTX) is $137.47M
The stock symbol (or ticker) of Nanobiotix is NBTX